Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5907_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
16 Мб
Скачать
☆
84
Nano Physical Pharmaceutics of Micelle-Based Systems
copolymers. Cui et al. have synthesized a high-molecular polymer mPEG-S-S-C16 with redox properties and used it to load the chemotherapy drug DOX. In vitro experiments show that under
         
disintegrated, and the wrapped DOX can be quickly released, and

2.5.6.3 Temperature-responsive micelles
Temperature is one of the most common sources of stimulation. Temperature-responsive polymeric micelles are assembled from copolymers with temperature-responsive blocks, where the aqueous properties of such copolymers change drastically at a certain temperature and the corresponding micelles release the drug through phase inversion. The temperature at which the transition occurs is referred to as lower critical solution temperature (LCST) or upper critical solution temperature (UCST) of the polymer. When the temperature is below LCST or above UCST, hydrogen bonds are formed between polymer and water and dissolve. When the temperature is above LCST or below UCST, the hydrogen bonds between water and polymer chains are broken and polymer precipitates. Currently, the most widely used temperature-responsive polymer is PNIPAAm when LCST is around 32 °C. In addition, Pluronics and P(HPMAm-Lacn) are
         
thermo-responsive poly(N-isopropylacrylamide-b-lauryl acrylate) (PNIPAAm-b-PLA) with tailored molecular weight through reversible addition-fragmentation chain-transfer (RAFT) polymerization to prepare drug-loaded smart micelle. The micelle experienced phase transition when the temperature rise up above the LCST and showed a sustained drug release rate [54].
2.5.6.4 Photo-responsive micelles
Photo-responsive micelles usually undergo structural

mainly through photo-induced transition of hydrophobicity– hydrophilicity or photo-cleavage reaction [55, 56]. Photochromic moieties such as coumarin, azobenzene, spiropyran, and 2-diazo-

Summary and Perspective

85
1,2-naphthoquinone are commonly introduced to construct photo-responsive block polymers. For example, The conformation of azobenzene groups and its derivatives changes from the apolar trans form to the polar cis form upon light irradiation (340–380 nm), then reforms to the orginal state after being exposed to irradiation at 420–490 nm or put into the dark. Compared with the cis-azo bond (dipole moment, μ = 3D), the trans-azo bond has a smaller polarity (dipole moment, μ = 0D) and stronger hydrophobicity, which may be utilized to control the assembly and disruption of azo-containing polymeric micelles in repeated cycles and facilitate drug release. Spiropyran is another promising photoisomerization group which can exist in two states, the hydrophilic zwitterionic merocyanine state and the hydrophobic SP state. These two states can transform into each other through a reversible isomerization either upon visible light (620 nm) irradiation (from hydrophilic to hydrophobic) or the UV (365 nm) irradiation (from hydrophobic to hydrophilic). Block copolymer with spiropyran showed improved light
       
hydrophilic and hydrophobic state compared with azo moieties.
2.6 Summary and Perspective
Polymeric micelles have shown various advantages as nanocarriers for drug delivery. They can realize the solubilization of water­insoluble drugs through hydrophobic interactions, and achieve enrichment in tumor tissues through enhanced permeability
              in vitro and in
vivo environments, and the complex composition of our internal environment (e.g., blood) encountered in practical applications, there are multiple interactions between micelles and biological macromolecules, which makes the precise and rational design of micelles a great challenge. At the same time, the special pathological conditions of tumor microenvironment have stricter requirements on the targeting and nanomedicine. Only when our understanding of disease physiology is matched by advances in
86
Nano Physical Pharmaceutics of Micelle-Based Systems
materials science, will it be possible to achieve larger breakthroughs

This chapter attempts to link the physical and chemical parameters of micelles with interactions in vivo, for example, how to regulate the particle size and zeta potential of the corresponding
                 
the chemical structure of amphiphilic polymers. It aims to provide theoretical basis and guidance for the precise design of micelles to

for tumors.
References
1. Torchilin VP, J Controll Release 2001, 73 Gupta
technologies,

80–118.
for the
for Poorly Water-Soluble Drugs
Solvents and Self-Organization
Tuzar Z, eds), Springer, Netherlands: Dordrecht, 1996, pp. 19–32.
9. Jean FG,
Interface Sci 2011

184–202.
A, Cardiovascular nanomedicine:
Nanomaterials
in
   
S,
Vaze OS, Movassaghian S, Torchilin
delivery
Anionic Polymerization

of poorly soluble
Adv. Colloid Interface Sci
J Phys Chem
J Colloid Interface Sci
and nonequilibrium
Proc Natl Acad Sci
J Pharm Sci 1976 65


, 162
Nanomedicine

1974 71
      
, , 1541–1544.
2021
16 Eur J Pharm Sci 2016, 83,

, Springer: Tokyo,

materials
in
Pharmacology

Adv Drug Deliv Rev 2020 156
drugs,
. 2014, 203
1951 55
of Polymers
, 
Drug
in
, 51–54.
, , 644–655.
, , 634–641.
1968 27
Z-R, Sakuma
VP, Polymeric
Delivery
polymer in
2015

SE, Munk P,
and
S,
, ,
micelles
Strategies
micelles,
Adv Colloid
References
87
15. Gohy J-F, Block copolymer micelles, in (Abetz V, ed), Springer, Berlin Heidelberg: Berlin, Heidelberg, 2005, pp. 65–
Block Copolymers II
136.
  
micelles

in
(Alexandridis
Br Polymer J
  
nonaqueous
P, Lindman
1984
16  
solution,
B, eds), Elsevier
in Amphiphilic
Science

Block
Copolymers
B.V., Amsterdam,
2000, pp. 115–149.
P, Modelling
solvent,
in Amphiphilic
of the
self-assembly
Block
of block
Copolymers
copolymers
P,
in selective
Lindman
B,
eds), Elsevier Science B.V., Amsterdam, 2000, pp. 13–40.
19. Daoud M, Cotton JP, J Phys France
Macromolecules 1983
  

Macromolecules
Li W, Nakayama M, Akimoto J, Okano
, 43
J Chem Phys
 
, 531–538.
16
1983, 79
1996
29
T,
Polymer

20
, 8999–8999.
11

,
52,

24. Nagarajan R, , Li W, Li J, Gao
Biomaterials
Li W, Zhao H, Qian W, 32Li H, Zhang

Langmuir
J, Li B, , Xia
2011
2002
Y, Meng 18Y, Yu Y, Chen H, Dai J, Wang H, Guo Y,
, 3832–3844.
Biomaterials
      
L, Ye Z, Zhang
G, , Xia
2012
33, 5349–5362.
M, Li J, Gao J,
Int J Nanomedicine 2018 13
, ,
2921–2942.
  
Bioactive
Polymeric Systems 1985
531–585.

Macromolecules 1996,
29, ,

  , 

Coudane J, El Omar F, Nottelet B,

 J Polym SciPart B: Polym Phys ,
, 924–934.
56
W, Zhao H, Qian W, Li H, Zhang

Adv Drug Deliv Rev

J Mater Chem B 2016 4
L, Ye Z, Zhang
Biomaterials
2012
64, 
J Polym Res 2014,
G, , Xia
2012
33, 5349–5362.

, 6228–6239.
, 452.
21
2018
M, Li J, Gao J,
88
Nano Physical Pharmaceutics of Micelle-Based Systems
 󰏩 , ,

Macromolecules 1996
29
     
Drug Deliv Rev 2001,
Adv ,
47
113–131.
,
Adv Drug Deliv Rev
W, Masamichi
2010
J Pharm Sci
N, Jun A, Teruo
, 131–135.
63
2008
O,
Polymer 972011, 
52  

 
Doris E, , 5, 1955–1960.
Nanoscale
D, Zhou Y, Li X, Qu X,
ACS Appl Mater Interfaces
 
Cho C-S,
283

J Control Release
B, Fang
C, You MX, Zhang

     
    
2013
Deng
Y, Wang Z, He C, Zou Y, Jin Y, Liu Y,
2017
, 9, 6916–6930.
 
, 
1998
Y, 51Fu S, Pei Y, ,
Colloid

Langmuir , 22,
  
Polym Sci 2005
2006

Toleikis
Biointerfaces 1999 16
,
     
P, Embree L, Hunter WL,
Chem Rev
Colloids Surf B:
2016, 116,
2602–2663.

 
Adv Colloid Interface Sci
Wang
2018
Z, Deng
, 535
X, Ding
, 253–260.
Fleige E, Quadir MA, Haag R,
51. Yang
YQ, Lin WJ, Zhao B, Wen XF,
28
, 8251–8259.
Wang C, Wang G, Wang Z, Zhang X,
2022,
307
J, Zhou
W, Zheng X, Tang G,
Polymer
Adv Drug Deliv Rev
Guo XD, Zhang
Int J Pharm
2009 50
2012
64
LJ,
Langmuir 2012
Chemistry – A Eur J 2011, 17,
3322–3325.
53.
Sarisozen C, responsive drug
delivery,
Drug
Delivery
Joshi U,
polymeric
in
Applications
Mendes
micelles
Stimuli
LP,
for
Responsive
Torchilin VP,
extracellular
Polymeric
ASH, Abu-Thabit
10
- Stimuli-
and
intracellular
Nanocarriers
for
NY, eds),
Woodhead Publishing, 2019, pp. 269–304.
,
References
89
54. Ghasemi S, Ahmadi L, Farjadian, F, , ,

J Mater Sci 2022 57
Soft Matter 2014, 10, 6121–6138.
56. Sana B, Finne-Wistrand A, Pappalardo D, Mater Today Chem 2022 25, 100963.
,
Chapter 3
Nano Physical Pharmaceutics of Liposome-Based System
Nian Huang,
a
Mengxin Zhao,a Jian Wang,b and Wei Li
a
a
Department of Nanomedicine, Naval Medical University,
Shanghai 200433, China
National Advanced Medical Engineering Research Center,
Shanghai 201203, China
liwei_dds@163.com

3.1 Classification of Liposome

                                                                      
Nano Physical Pharmaceutics
Edited by Wei Li Copyright © 2025 Jenny Stanford Publishing Pte. Ltd.
ISBN 978-981-4968-52-2 (Hardcover), 978-1-003-51393-3 (eBook)
www.jennystanford.com
92
Nano Physical Pharmaceutics of Liposome-Based System
         
                                                   
Figure 3.1 Schemac diagram of the structures of liposomes with dierent
structures.

3.2 Preparation of Liposomes

                  
3.2.1 Thin-Film Hydraon Method
I       


Preparation of Liposomes
93
                                                                               

3.2.2 Reverse-Phase Evaporation Method

                                                                  

3.2.3 Injection Method

                                                                